Wegovy vs Mounjaro: Complete Treatment Comparison
Understanding Mounjaro vs Wegovy: Different Mechanisms Explained
When evaluating Mounjaro vs Wegovy, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone GLP-1 to promote feelings of fullness and reduce appetite. Mounjaro uses tirzepatide, which targets both GIP and GLP-1 receptors simultaneously - making it a dual agonist treatment. Both prescription-only medicines work by influencing appetite centres in the brain, but their receptor targeting differs significantly.
This mechanistic difference in the Mounjaro vs Wegovy comparison may influence how each treatment works for individual patients. Wegovy has established clinical evidence from the STEP trial programme, whilst Mounjaro draws from the SURPASS studies for weight management indications. Both require dose escalation protocols and must be used alongside a reduced-calorie diet and increased physical activity. Your prescriber at EverydayMeds can assess which mechanism may be more suitable based on your medical history and treatment goals.
Wegovy vs Mounjaro Pricing: Complete Cost Breakdown
Understanding the financial aspect of Mounjaro vs Wegovy helps inform your treatment decision. Wegovy follows a 5-dose escalation: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and 2.4mg maintenance (£209.99). Mounjaro requires 6 doses: 2.5mg through to 15mg maximum. New customers benefit from code FIRST40 whilst returning patients use DOSE25, both applied at checkout to reach these final prices. Our bundle options provide convenience for multi-month supplies without requiring separate orders.
The Wegovy vs Mounjaro cost comparison extends beyond individual pen prices to consider treatment duration and maintenance requirements. Wegovy reaches maintenance dosing at week 17, whilst Mounjaro's escalation timeline differs. Both treatments represent long-term commitments, as clinical evidence suggests weight regain occurs when treatment stops. EverydayMeds offers flexible ordering through our bundle system, ensuring consistent supply throughout your weight management journey with either treatment option.
Clinical Evidence: Mounjaro vs Wegovy Trial Data
The clinical evidence supporting both treatments in this Mounjaro vs Wegovy comparison comes from rigorous phase 3 trials. Wegovy's STEP programme demonstrated significant weight reduction, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial confirmed sustained efficacy at 2 years, whilst SELECT showed cardiovascular benefits.
Mounjaro's evidence base stems from the SURPASS trials, though comparing trial outcomes directly between Mounjaro vs Wegovy isn't appropriate due to different study designs, populations, and endpoints. Both treatments demonstrated clinically meaningful weight reduction when combined with lifestyle interventions. Individual responses may vary significantly, and your EverydayMeds prescriber will consider your specific circumstances when determining suitability for either option.
How Wegovy Works in Your Mounjaro vs Wegovy Evaluation
Wegovy functions as a GLP-1 receptor agonist, replicating the action of naturally occurring incretin hormones that regulate blood sugar and appetite. Once injected weekly via the FlexTouch pen, semaglutide binds to GLP-1 receptors in the brain's appetite centres, promoting satiety signals and reducing food cravings. This mechanism may help patients feel satisfied with smaller portion sizes and experience fewer between-meal hunger pangs. The treatment also slows gastric emptying, contributing to prolonged feelings of fullness after eating. These combined effects support adherence to reduced-calorie eating plans essential for successful weight management outcomes.
EverydayMeds Ordering Process for Wegovy or Mounjaro
Ordering either treatment in your Mounjaro vs Wegovy decision involves our streamlined 3-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within 3 working days (express 24-hour service available), ensuring clinical appropriateness before dispensing these prescription-only medicines. Upon approval, your chosen treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance throughout the process. Payment includes applicable discount codes, with FIRST40 for new customers and DOSE25 for returning patients applied automatically at checkout.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements represent a key practical difference in the Mounjaro vs Wegovy comparison. Wegovy requires refrigeration at 2-8°C before first use but tolerates room temperature (below 30°C) for up to 6 weeks once removed from the fridge - significantly longer than Mounjaro's 21-day room temperature limit. This makes Wegovy more suitable for extended travel or situations where refrigeration access is limited. Both treatments use pre-filled pen devices for once-weekly subcutaneous injection, though the pen designs differ between manufacturers. Dose escalation is mandatory for both options, requiring adherence to specific timing protocols to minimise potential side effects and optimise treatment tolerance.
Dual Agonist vs Single Agonist: Advanced Mounjaro vs Wegovy Science
The scientific distinction between Mounjaro and Wegovy centres on receptor targeting breadth. Wegovy's semaglutide exclusively activates GLP-1 pathways, providing proven efficacy through this single mechanism. Mounjaro's tirzepatide simultaneously engages both GIP and GLP-1 receptors, theoretically offering broader metabolic effects through dual activation. This represents different philosophical approaches to weight management pharmacotherapy - focused single-target action versus comprehensive dual-pathway intervention.
Neither approach is inherently superior in the Mounjaro vs Wegovy debate, as individual patient factors determine treatment response. Some patients may respond preferentially to GLP-1 monotherapy, whilst others might benefit from dual agonism. Your EverydayMeds prescriber evaluates personal medical history, concurrent conditions, and treatment preferences when recommending between these options, ensuring the most appropriate choice for your specific circumstances.
Making Your Mounjaro vs Wegovy Decision with EverydayMeds
Choosing between these treatments doesn't require navigating multiple pharmacies or comparing different suppliers. EverydayMeds provides both Wegovy and Mounjaro through our comprehensive weight management service, offering prescriber guidance, transparent pricing, and reliable supply. Our clinical team understands the nuances of each treatment, helping patients navigate the Mounjaro vs Wegovy decision based on medical suitability rather than availability constraints. Begin your assessment today using discount codes FIRST40 (new customers) or DOSE25 (returning customers) at https://everydaymeds.co.uk/collections/weight-loss. Both treatments require ongoing commitment and lifestyle modifications, but with professional support, you can determine which option aligns best with your weight management objectives and practical requirements.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
